ClinicalTrials.gg
CompletedNCT03404206Updated Jul 18, 2019Results posted

A Trial to Compare the Duration of Analgesic Efficacy and Safety of Naproxen Sodium Tablets and Ibuprofen Tablets in Postsurgical Dental Pain

A Phase 4 interventional study of Naproxen Sodium (Aleve, BAY117031) and Ibuprofen (Advil) in Pain, Postoperative, sponsored by Bayer. Completed at 1 site in United States. Open to participants aged 16 Years to 40 Years. Per ClinicalTrials.gov, last updated 2019-07-18.

Sponsored by Bayer · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
387
Allocation
Randomized
Ages
16 Years to 40 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 13 studies testing naproxen in Pain, Postoperative — 2 open to participants now, 2 under way, 1 of them phase 3. Naproxen · Pain, Postoperative.

Enrollment
4th of 13
387 · median 200
Started
2018
the only one that year
Phase 4
4 of 13
1 open now
Registered
7th of 13
by date
Lead sponsor
5 of 13
Bayer

Among the 13 studies testing naproxen in Pain, Postoperative, this one is the 4th largest by enrollment, is the only one that started in 2018, is one of 4 in phase 4, and was the 7th registered.

Pain, Postoperative

5,662 studies on the registry are indexed under Pain, Postoperative; 1,238 are open to participants now.

Browse Pain, Postoperative studies →

Open to participants now

2 of the 13 studies testing naproxen in Pain, Postoperative are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

About naproxen

Naproxen: first FDA approval 1976 (NAPROSYN). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 678 Pain, Postoperative studies recruiting now, 240 (35%) set no upper age limit and 328 (48%) stop at 75 or younger; 74 take children under 18; 129 take healthy volunteers.

This study: 16 Years to 40 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies testing naproxen in Pain, Postoperative, or all of them as a file.
02

Study summary

To compare the duration of analgesic efficacy as determined by the time to rescue medication of a single oral dose of naproxen sodium 440 mg (2 x 220 mg tablets) relative to ibuprofen 400 mg (2 x 200 mg tablets) and placebo over 24 hours in subjects experiencing moderate to severe post-impaction surgery dental pain.

To compare the overall analgesic effect (SPID 0-24) of a single dose of naproxen sodium 440 mg (2 x 220 mg tablets) relative to ibuprofen 400 mg (2 x 200 mg tablets) and placebo.

To compare the overall relief from pain (TOTPAR 0-24) of a single dose of naproxen sodium 440 mg (2 x 220 mg tablets) relative to ibuprofen 400 mg (2 x 200 mg tablets) and placebo.

03

Conditions studied

  • Pain, Postoperative

Browse trials for

Keywords

  • Postsurgical pain
04

Who can participate

Ages eligible
16 Years to 40 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy, ambulatory, male or female volunteers 16-40 years of age;
  • 18.0 to 30.0 kg/m\^2 inclusive;
  • Scheduled to undergo surgical removal of at least 2 mandibular partial or full bony impacted third molars. Up to two maxillary third molars may be removed regardless of impaction level. Supernumerary teeth present may also be removed at the discretion of the oral surgeon;
  • Mandibular molars must demonstrate modified Demirjian root classification stage D, E, F, G or H;

Exclusion criteria

Exclusion Criteria:

  • History of to naproxen sodium, ibuprofen, nonsteroidal anti-inflammatory drugs (NSAIDS), aspirin, similar pharmacological agents, local anesthetics, rescue medication or components of the products;
  • Evidence or history of (in the judgment of the investigator) hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic diseases, or within the last 5 years;
  • Relevant concomitant disease such as asthma (exercise induced asthma is permitted)
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
387 participants (actual)

Study arms

  • Experimental
    Naproxen Sodium (Aleve, BAY117031)

    Participants received one single dose of 440 mg naproxen sodium tablets (200 mg x 2 tablets, oral) after randomization

    Drug: Naproxen Sodium (Aleve, BAY117031)

  • Active comparator
    Ibuprofen (Advil)

    Participants received one single dose of 400 mg ibuprofen tablets (200 mg x 2 tablets, oral) after randomization

    Drug: Ibuprofen (Advil)

  • Placebo comparator
    Placebo

    Participants received one single dose of matching placebo tablets (2 tablets, oral) after randomization

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Time to First Use of Rescue Medication

    Time to first use of rescue medication was estimated using Kaplan-Meier method. If a subject did not take the rescue medication during the treatment period, (s)he was censored at the time of last assessment.

    Time frame: Up to 24 hours

Secondary outcomes

  1. Sum of Pain Intensity Difference (SPID)

    Pain intensity was measured using Numerical Rating Scale (from 0 to 10: 0 = no pain, 10 = worst possible pain). For each postdose time point, pain intensity differences (PIDs) were derived by subtracting the pain intensity at the postdose time point from the baseline intensity score (baseline score - post-baseline score). A positive difference was indicative of improvement. Time-weighted sum of pain intensity differences (SPIDs) were calculated by multiplying the PID score at each postdose time point by the duration (in hours) since the preceding time point and then summing these values.

    Time frame: Up to 24 hours

  2. Total Pain Relief (TOTPAR)

    Pain relief was measured using Categorical Pain Relief Rating Scale (0 = No relief, 1 = a little relief, 2 = some relief, 3 = a lot of relief, 4 = complete relief). Total pain relief scores (TOTPARs) were calculated by multiplying the pain relief score at each postdose time point by the duration (in hours) since the preceding time point and then summing these values.

    Time frame: Up to 24 hours

07

Results

Posted Jul 18, 2019

Participant flow

The study was conducted at one center in the United States, between 12 February 2018 (first patient first visit) and 10 July 2018 (last patient last visit).

Participant flow — Overall Study
MilestoneNaproxen Sodium (Aleve, BAY117031)Ibuprofen (Advil)Placebo
Started16616655
Completed16216455
Not completed420
Withdrew: Withdrawal by subject110
Withdrew: Lost to follow-up310

Outcome measures

PrimaryTime to First Use of Rescue Medication

Time to first use of rescue medication was estimated using Kaplan-Meier method. If a subject did not take the rescue medication during the treatment period, (s)he was censored at the time of last assessment.

Time frame:
Up to 24 hours
Reported as:
Number · hours
Time to First Use of Rescue Medication
hoursNaproxen Sodium (Aleve, BAY117031)Ibuprofen (Advil)Placebo
Minimum1.221.221.18
25th Percentile11.0178.2672.117
50th PercentileNA10.5332.533
75th PercentileNA14.11712.100
Maximum22.1718.2821.75
Statistical analysis
  • Naproxen Sodium (Aleve, BAY117031) vs Ibuprofen (Advil) · Log Rank · p = <0.001
  • Naproxen Sodium (Aleve, BAY117031) vs Placebo · Log Rank · p = <0.001
SecondarySum of Pain Intensity Difference (SPID)

Pain intensity was measured using Numerical Rating Scale (from 0 to 10: 0 = no pain, 10 = worst possible pain). For each postdose time point, pain intensity differences (PIDs) were derived by subtracting the pain intensity at the postdose time point from the baseline intensity score (baseline score - post-baseline score). A positive difference was indicative of improvement. Time-weighted sum of pain intensity differences (SPIDs) were calculated by multiplying the PID score at each postdose time point by the duration (in hours) since the preceding time point and then summing these values.

Time frame:
Up to 24 hours
Reported as:
Mean · Scores on a scale * hours
Sum of Pain Intensity Difference (SPID)
Scores on a scale * hoursNaproxen Sodium (Aleve, BAY117031)Ibuprofen (Advil)Placebo
Sum of Pain Intensity Difference (SPID)83.29 ± 57.17748.54 ± 40.7059.96 ± 58.197
Statistical analysis
  • Naproxen Sodium (Aleve, BAY117031) vs Ibuprofen (Advil) · ANCOVA · Least squares means: -34.73 · 95% CI -45.67 to -23.8
  • Naproxen Sodium (Aleve, BAY117031) vs Placebo · ANCOVA · Least squares means: -73.43 · 95% CI -89.01 to -57.85
  • Ibuprofen (Advil) vs Placebo · ANCOVA · Least squares means: -38.7 · 95% CI -54.29 to -23.11
SecondaryTotal Pain Relief (TOTPAR)

Pain relief was measured using Categorical Pain Relief Rating Scale (0 = No relief, 1 = a little relief, 2 = some relief, 3 = a lot of relief, 4 = complete relief). Total pain relief scores (TOTPARs) were calculated by multiplying the pain relief score at each postdose time point by the duration (in hours) since the preceding time point and then summing these values.

Time frame:
Up to 24 hours
Reported as:
Mean · Scores on a scale * hours
Total Pain Relief (TOTPAR)
Scores on a scale * hoursNaproxen Sodium (Aleve, BAY117031)Ibuprofen (Advil)Placebo
Total Pain Relief (TOTPAR)47.16 ± 28.22828.96 ± 21.09713.40 ± 23.328
Statistical analysis
  • Naproxen Sodium (Aleve, BAY117031) vs Ibuprofen (Advil) · ANCOVA · Least squares means: -18.21 · 95% CI -23.52 to -12.89
  • Naproxen Sodium (Aleve, BAY117031) vs Placebo · ANCOVA · Least squares means: -33.72 · 95% CI -41.29 to -26.14
  • Ibuprofen (Advil) vs Placebo · ANCOVA · Least squares means: -15.51 · 95% CI -23.09 to -7.93

Adverse events

Collected over From start of study drug up to 10 days after the administration of study drug. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Naproxen Sodium (Aleve, BAY117031)0/166 (0%)1/166 (0.6%)25/166 (15.1%)
Placebo0/55 (0%)0/55 (0%)16/55 (29.1%)
Ibuprofen (Advil)0/166 (0%)0/166 (0%)31/166 (18.7%)
Most frequent serious events
Most frequent serious events
EventNaproxen Sodium (Aleve, BAY117031)PlaceboIbuprofen (Advil)
AppendicitisInfections and infestations1/1660/550/166
Most frequent other events
Showing 10 of 28
Most frequent other events
EventNaproxen Sodium (Aleve, BAY117031)PlaceboIbuprofen (Advil)
NauseaGastrointestinal disorders9/16611/5517/166
VomitingGastrointestinal disorders1/1667/557/166
HeadacheNervous system disorders3/1667/556/166
DizzinessNervous system disorders4/1661/555/166
Alveolar osteitisInfections and infestations4/1660/551/166
Abdominal pain upperGastrointestinal disorders0/1661/550/166
ConstipationGastrointestinal disorders0/1661/550/166
PyrexiaGeneral disorders0/1661/551/166
Pain in extremityMusculoskeletal and connective tissue disorders0/1661/550/166
Oropharyngeal painRespiratory, thoracic and mediastinal disorders2/1660/550/166

Baseline characteristics

Safety Population (included all subjects who were randomized and took at least one dose of investigational product)

Age, Continuous
Age, Continuous(years)Naproxen Sodium (Aleve, BAY117031)Ibuprofen (Advil)PlaceboTotal
Mean19.0 ± 2.9619.0 ± 2.6219.0 ± 2.9119.0 ± 2.80
Sex: Female, Male
Sex: Female, Male(Participants)Naproxen Sodium (Aleve, BAY117031)Ibuprofen (Advil)PlaceboTotal
Female778930196
Male897725191
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Naproxen Sodium (Aleve, BAY117031)Ibuprofen (Advil)PlaceboTotal
Hispanic or Latino23251058
Not Hispanic or Latino14314145329
Unknown or Not Reported0000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Naproxen Sodium (Aleve, BAY117031)Ibuprofen (Advil)PlaceboTotal
White14814848344
Black or African American2417
American Indian or Alaska Native3429
Asian1214
Native Hawaiian or Other Pacific Islander1315
Other115218
Pain Intensity Score
Pain Intensity Score(Participants)Naproxen Sodium (Aleve, BAY117031)Ibuprofen (Advil)PlaceboTotal
No Pain (0)0000
Mild Pain (1)0000
Moderate Pain (2)696723159
Severe Pain (3)979932228
08

Study locations

1 site
  • Jean Brown Research
    Salt Lake City, Utah 84124, United States
09

References and documents

Publications

  • Cooper SA, Desjardins P, Brain P, Paredes-Diaz A, Troullos E, Centofanti R, An B. Longer analgesic effect with naproxen sodium than ibuprofen in post-surgical dental pain: a randomized, double-blind, placebo-controlled, single-dose trial. Curr Med Res Opin. 2019 Dec;35(12):2149-2158. doi: 10.1080/03007995.2019.1655257. Epub 2019 Aug 27. PubMed 31402718 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2018 to primary completion in Jul 2018, 4 months.

Results were first posted in Jul 2019, 1 year after primary completion.

Of 542 phase 4 interventional studies under Pain, Postoperative, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 32. This study's 4 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 12, 2018
First posted
Jan 19, 2018
StartActual
Feb 12, 2018
Primary completionActual
Jul 6, 2018
CompletionActual
Jul 10, 2018
Results first posted
Jul 18, 2019
Last update
Jul 18, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 18, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03404206
Lead sponsor
Bayer
Responsible party
Sponsor
First posted
Jan 19, 2018
Start date
Feb 12, 2018
Primary completion
Jul 6, 2018
Completion
Jul 10, 2018
Results posted
Jul 18, 2019
Last update
Jul 18, 2019

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Naproxen

Start the discussion